Cargando…

Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring

AIMS: To explore the effects of dapagliflozin on congestion through CardioMEMS (Abbott Inc., Atlanta, USA) and Cordella™ pulmonary artery Sensor (Endotronix Inc., Lisle, Il, USA) devices, which are implantable systems that provide real‐time remote monitoring of pulmonary artery pressure (PAP). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullens, Wilfried, Martens, Pieter, Forouzan, Omid, Dauw, Jeroen, Vercammen, Jan, Luwel, Evert, Ceyssens, Wendy, Kockaerts, Veerle, Ameloot, Koen, Dupont, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524114/
https://www.ncbi.nlm.nih.gov/pubmed/32588973
http://dx.doi.org/10.1002/ehf2.12850
_version_ 1783588492674072576
author Mullens, Wilfried
Martens, Pieter
Forouzan, Omid
Dauw, Jeroen
Vercammen, Jan
Luwel, Evert
Ceyssens, Wendy
Kockaerts, Veerle
Ameloot, Koen
Dupont, Matthias
author_facet Mullens, Wilfried
Martens, Pieter
Forouzan, Omid
Dauw, Jeroen
Vercammen, Jan
Luwel, Evert
Ceyssens, Wendy
Kockaerts, Veerle
Ameloot, Koen
Dupont, Matthias
author_sort Mullens, Wilfried
collection PubMed
description AIMS: To explore the effects of dapagliflozin on congestion through CardioMEMS (Abbott Inc., Atlanta, USA) and Cordella™ pulmonary artery Sensor (Endotronix Inc., Lisle, Il, USA) devices, which are implantable systems that provide real‐time remote monitoring of pulmonary artery pressure (PAP). METHODS AND RESULTS: Single‐centre open label observational pilot trial, to investigate the short‐term effects of dapagliflozin in consecutive heart failure and reduced ejection fraction patients with elevated PAP between October and December 2019, previously implanted with CardioMEMS or Cordella™ Sensor. Changes in PAP were evaluated with an area under the curve methodology to estimate the total sum increase or decrease in pressures (mmHg/day) for 7 days before and after starting dapagliflozin relative to the first day of each period. Nine patients (72 ± 10 years, N‐terminal pro b‐type natriuretic peptide 1027 ± 510 pg/mL, estimated glomerular filtration rate 45 ± 15 mL/kg/m2, left ventricular ejection fraction 35 ± 10%), all on optimal guideline‐directed therapy was included. The mean PAP was reduced from 42 ± 9.16 to 38 ± 9.95 mmHg with dapagliflozin therapy (P < 0.05). The average area under the curve for the week leading to dapagliflozin therapy remained unchanged compared to the drop observed for the week after therapy (P < 0.05). Interestingly, the drop in PAP occurred within the first 2 days of dapagliflozin and remained stable for the week following the start of the therapy. CONCLUSIONS: This is the first study to demonstrate a direct effect of dapagliflozin on achieving effective hemodynamic decongestion, providing further mechanistic data regarding the potential mechanisms of sodium‐glucose co‐transporter‐2 inhibitor benefits on heart failure.
format Online
Article
Text
id pubmed-7524114
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75241142020-10-02 Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring Mullens, Wilfried Martens, Pieter Forouzan, Omid Dauw, Jeroen Vercammen, Jan Luwel, Evert Ceyssens, Wendy Kockaerts, Veerle Ameloot, Koen Dupont, Matthias ESC Heart Fail Short Communication AIMS: To explore the effects of dapagliflozin on congestion through CardioMEMS (Abbott Inc., Atlanta, USA) and Cordella™ pulmonary artery Sensor (Endotronix Inc., Lisle, Il, USA) devices, which are implantable systems that provide real‐time remote monitoring of pulmonary artery pressure (PAP). METHODS AND RESULTS: Single‐centre open label observational pilot trial, to investigate the short‐term effects of dapagliflozin in consecutive heart failure and reduced ejection fraction patients with elevated PAP between October and December 2019, previously implanted with CardioMEMS or Cordella™ Sensor. Changes in PAP were evaluated with an area under the curve methodology to estimate the total sum increase or decrease in pressures (mmHg/day) for 7 days before and after starting dapagliflozin relative to the first day of each period. Nine patients (72 ± 10 years, N‐terminal pro b‐type natriuretic peptide 1027 ± 510 pg/mL, estimated glomerular filtration rate 45 ± 15 mL/kg/m2, left ventricular ejection fraction 35 ± 10%), all on optimal guideline‐directed therapy was included. The mean PAP was reduced from 42 ± 9.16 to 38 ± 9.95 mmHg with dapagliflozin therapy (P < 0.05). The average area under the curve for the week leading to dapagliflozin therapy remained unchanged compared to the drop observed for the week after therapy (P < 0.05). Interestingly, the drop in PAP occurred within the first 2 days of dapagliflozin and remained stable for the week following the start of the therapy. CONCLUSIONS: This is the first study to demonstrate a direct effect of dapagliflozin on achieving effective hemodynamic decongestion, providing further mechanistic data regarding the potential mechanisms of sodium‐glucose co‐transporter‐2 inhibitor benefits on heart failure. John Wiley and Sons Inc. 2020-06-26 /pmc/articles/PMC7524114/ /pubmed/32588973 http://dx.doi.org/10.1002/ehf2.12850 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Communication
Mullens, Wilfried
Martens, Pieter
Forouzan, Omid
Dauw, Jeroen
Vercammen, Jan
Luwel, Evert
Ceyssens, Wendy
Kockaerts, Veerle
Ameloot, Koen
Dupont, Matthias
Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
title Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
title_full Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
title_fullStr Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
title_full_unstemmed Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
title_short Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
title_sort effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524114/
https://www.ncbi.nlm.nih.gov/pubmed/32588973
http://dx.doi.org/10.1002/ehf2.12850
work_keys_str_mv AT mullenswilfried effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring
AT martenspieter effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring
AT forouzanomid effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring
AT dauwjeroen effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring
AT vercammenjan effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring
AT luwelevert effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring
AT ceyssenswendy effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring
AT kockaertsveerle effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring
AT amelootkoen effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring
AT dupontmatthias effectsofdapagliflozinoncongestionassessedbyremotepulmonaryarterypressuremonitoring